[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335011-105":59,"doc-detail-335011-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","long-term-outcome-after-helical-tomotherapy-following-breast-conserving-surgery-for-ductal-carcinoma-in-situ","Long-term Outcome After Helical Tomotherapy Following Breast Conserving Surgery for Ductal Carcinoma In Situ","","Retrospective analysis evaluated long-term outcomes and adverse events after adjuvant helical tomotherapy (hT) following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS). Twenty-eight DCIS patients received postoperative hT between 2011 and 2020; hT was selected to achieve optimal target coverage and tolerable lung and heart doses when tangential 3D-CRT was presumed unfavorable. Median follow-up was 61 months. Overall survival remained 100% at 1, 3, and 5 years with no secondary cancers or local/invasive recurrences. Acute toxicities mainly included dermatitis and fatigue, while late effects were limited to surgical scars and hyperpigmentation, with no AEs above grade 3.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-outcome-after-helical-tomotherapy-following-breast-conserving-surgery-for-ductal-carcinoma-in-situ/335011/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-outcome-after-helical-tomotherapy-following-breast-conserving-surgery-for-ductal-carcinoma-in-situ/335011.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study goal regarding helical tomotherapy after BCS for DCIS?","Question",{"text":112,"@type":113},"To investigate long-term outcomes and adverse events associated with adjuvant radiotherapy using helical tomotherapy after breast-conserving surgery for DCIS.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients treated and what time window was included?",{"text":117,"@type":113},"Twenty-eight patients underwent postoperative helical tomotherapy between 2011 and 2020, with the median interval from BCS to hT start reported as 5 weeks.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings on survival and recurrence during follow-up?",{"text":121,"@type":113},"Overall survival was 100% at 1, 3, and 5 years. No secondary cancers, local recurrence, or invasive breast cancer were observed during the follow-up period.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335011,1790013675,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Long-term Outcome After Helical Tomotherapy Following Breast Conserving Surgery for Ductal Carcinoma In Situ  \nHenrik Hauswald, MD 1,2 , Michael Schempp, MS3,  \nPauline Liebig, MS3, Sebastian Hoefel, MS3, Jürgen Debus, MD, PhD 1,4, Peter E. Huber, MD, PhD 1, and Felix Zwicker, MD 1,3  \nTechnology in Cancer Research & Treatment  \nVolume 23: 1-13  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338241264847](DOI: 10.1177/15330338241264847)[ ](DOI: 10.1177/15330338241264847)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nAbstract  \nBackground: This retrospective study aimed to investigate the outcomes and adverse events (AEs) associated with adjuvant radiotherapy with helical tomotherapy (hT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) . Methods: Twenty-eight patients with DCIS underwent postoperative hT between 2011 and 2020. hTwas chosen since it provided optimal target coverage and tolerable organ-at-risk doses to the lungs and heart when tangential 3-dimensional conformal radiotherapy (3D-CRT) was presumed to provide unfavorable dosimetry. The median total (single) dose was 50.4 Gy (1.8 Gy) . The median time between BCS and the start of hT was 5 weeks (range, 4-38 weeks) . Statistical analysis included local recurrence-free survival, overall survival (OS), and secondary cancer-free survival. AEs were classiﬁed according to the Common Toxicity Criteria for Adverse Events, version 5 . Results: The patients’ median age was 58 years. The median follow-up period was 61 months (range, 3-123 months). The 1-, 3-, and 5-year OS rates were 100% each. None of the patients developed secondary cancer, local recurrence, or invasive breast cancer during follow-up. The most common acute AEs were dermatitis (n = 27), fatigue (n = 4), hyperpigmentation (n = 3), and thrombocytopenia (n = 4) . The late AE primarily included surgical scars (n = 7) and hyperpigmentation (n = 5) . None of the patients experienced acute or late AEs > grade 3 . The mean conformity and homogeneity indices were 0.9 (range, 0.86-0.96) and 0.056 (range, 0.05-0.06), respectively. Conclusion: hT after BCS for DCIS is a feasible and safe form of adjuvant radiotherapy for patients in whom 3D-CRT is contraindicated due to unfavorable dosimetry. During follow-up, there were no recurrences, invasive breast cancer diagnoses, or secondary cancers, while the adverse effects were mild.  \nKeywords  \nDCIS, ductal carcinoma in situ, radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, breast cancer  \nAbbreviations  \nAEs, adverse events; BCS, breast-conserving surgery; CAD, coronary artery disease; CI, conformity index; CT, computed tomography; CTCAE, Common Toxicity Criteria for Adverse Events; DCIS, ductal carcinoma in situ; D0.03cc, approximate maximum dose for organ at risk; DX%, dose covering X% of the volume; FiF, ﬁeld-in-ﬁeld; HI, homogeneity index; hT, helical tomotherapy; IMRT, intensity-modulated radiotherapy; LRFS, local recurrence-free survival; MLC, multileaf collimator; NRG, National Radiation Gynecology; OAR, organs at risk; OS, overall survival; PTV, planning target volume; RT, radiotherapy;  \n1 Clinical Cooperation Unit Molecular Radiation Oncology (E055), German Cancer Research Center (DKFZ), Heidelberg, Germany  \n2 RNS Gemeinschaftspraxis, Wiesbaden, Germany  \n3 Clinic and Practice of Radiation Oncology/Practice of Radiology, Konstanz, Germany  \n4 Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany  \nCorresponding Author:  \nHenrik Hauswald, RNS Gemeinschaftspraxis, German Cancer Research Centre (DKFZ) E055, Im Neuenheimer Feld 280, 69120 Heidelberg, Wiesbaden, Germany.  \nEmail: henrik.hauswald@dkfz-heidelberg.de  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommerci","cbCaiabxYR4hzSzA","https://ap.wps.com/l/cbCaiabxYR4hzSzA","pdf",2063511,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## DCIS overview and standard treatment\n## Evidence on mortality and recurrence risk","[{\"question\":\"What was the study goal regarding helical tomotherapy after BCS for DCIS?\",\"answer\":\"To investigate long-term outcomes and adverse events associated with adjuvant radiotherapy using helical tomotherapy after breast-conserving surgery for DCIS.\"},{\"question\":\"How were patients treated and what time window was included?\",\"answer\":\"Twenty-eight patients underwent postoperative helical tomotherapy between 2011 and 2020, with the median interval from BCS to hT start reported as 5 weeks.\"},{\"question\":\"What were the main findings on survival and recurrence during follow-up?\",\"answer\":\"Overall survival was 100% at 1, 3, and 5 years. No secondary cancers, local recurrence, or invasive breast cancer were observed during the follow-up period.\"}]","Long-term Outcome After Helical Tomotherapy Following Breast Conserving Surgery for Ductal Carcinoma In Situ | PDF",1790009219,33]